Jiangsu Cowin Biotech Co., Ltd. Class A

As of June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A carries a market capitalization of 2.06B, placing it among publicly traded companies globally. Its enterprise value stands at 1.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Jiangsu Cowin Biotech Co., Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A has 112.49M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.55, and the price-to-book ratio stands at 1.56.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.36B versus a market cap of 2.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A maintains a current ratio of 14.79, meaning it holds 14.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.27, indicating elevated leverage, while an interest coverage ratio of -113.21 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A posted a negative return on equity (ROE) of -7.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.45, reflecting losses generated across the asset base. The company generates approximately 268,889.83 in revenue per employee across its workforce of 785.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times Jiangsu Cowin Biotech Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A recorded 4.10M in income tax expense. The company reported a pretax loss of -98.29M and -99.60M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A's stock has declined approximately 31.44% over the past 52 weeks. The 50-day moving average sits at 20.63, while the 200-day moving average is 20.99.

Over the twelve months ended June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A generated 211.08M in revenue and converted that into -99.60M in net income, yielding earnings per share of -0.93. EBITDA reached -97.08M, while operating income came in at -97.89M.

As of June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A holds 756.03M in cash and equivalents against 43.35M in total debt, resulting in a net debt position of -209.77M. Total book value stands at 1.32B, with working capital of 840.78M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A posted a gross margin of 45.85, reflecting its pricing power and cost economics. The operating margin of -46.38 and net profit margin of -47.19 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.17 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.13, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Jiangsu Cowin Biotech Co., Ltd. Class A shareholders.

Jiangsu Cowin Biotech Co., Ltd. Class A's most recent stock split took place on June 12, 2023 with a 5:6 split ratio.

As of June 30, 2026, Jiangsu Cowin Biotech Co., Ltd. Class A has an Altman Z-Score of 8.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.